Gastroenterology
Volume 135, Issue 2 , Pages 459-467 , August 2008

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

  • Erik H.C.J. Buster

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Hajo J. Flink

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Yilmaz Cakaloglu

      Affiliations

    • Department of Gastroenterohepatology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
    • ,
  • Krzysztof Simon

      Affiliations

    • Department and Clinic of Infectious Diseases, Medical University Wroclaw, Wroclaw, Poland
    • ,
  • Jörg Trojan

      Affiliations

    • Department of Internal Medicine, Division of Gastroenterology, Johann Wolfgang Goethe University Medical Center, Frankfurt, Germany
    • ,
  • Fehmi Tabak

      Affiliations

    • Department of Infectious Diseases, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey
    • ,
  • Thomas M.K. So

      Affiliations

    • Department of Medicine, Princess Margaret Hospital, Hong Kong, China
    • ,
  • S. Victor Feinman

      Affiliations

    • Liver Disease Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    • ,
  • Tomasz Mach

      Affiliations

    • Department of Infectious Diseases and Hepatology, Jagiellonian University School of Medicine, Kraków, Poland
    • ,
  • Ulus S. Akarca

      Affiliations

    • Department of Gastroenterology, Ege University Faculty of Medicine, Izmir, Turkey
    • ,
  • Martin Schutten

      Affiliations

    • Department of Virology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Wanda Tielemans

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Anneke J. van Vuuren

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Bettina E. Hansen

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • Department of Epidemiology and Biostatistics, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Harry L.A. Janssen

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • Corresponding Author InformationAddress requests for reprints to: Harry L. A. Janssen, MD, PhD, Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, 's Gravendijkwal 230, Room Ha204, 3015 CE Rotterdam, The Netherlands.

Received 7 January 2008 ,Accepted 8 May 2008.

References 

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
  2. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745
  3. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191–211v
  4. Escorsell A, Mas A, de la Mata M. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl. 2007;13:1389–1395
  5. Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers (Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy). Gastroenterology. 1987;93:1236–1241
  6. Gigi E, Lalla T, Orphanou E, et al. Long term follow-up of a large cohort of inactive HBsAg (+)/HBeAg (−)/anti-HBe (+) carriers in Greece. J Gastrointestin Liver Dis. 2007;16:19–22
  7. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129
  8. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695
  9. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B (A meta-analysis). Ann Intern Med. 1993;119:312–323
  10. Pas SD, Fries E, De Man RA, et al. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol. 2000;38:2897–2901
  11. Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet. 1995;346:1085–1087
  12. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B (The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment). J Viral Hepat. 1998;5:389–397
  13. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804–810
  14. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427
  15. Lau GK, Piratvisuth T, Luo KX, et al. Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) one year post-treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol. 2006;44:S23
  16. Gish RG, Chang TT, De Man RA, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). Hepatology. 2005;42:267A;(abstr)
  17. Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology. 2006;44:222A;(abstr)
  18. Colonno RJ, Rose RE, Levine S, et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology. 2005;42:573A;(abstr)
  19. Poynard T, Chutaputti A, Hwang SG, et al. Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study. J Hepatol. 2007;46:S27;(abstr)
  20. van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut. 2003;52:420–424
  21. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617–624
  22. Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol. 2000;33:430–439
  23. Flink HJ, Buster EH, Merican I, et al. Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B. Gut. 2007;56:1485–1486
  24. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660–1667
  25. Fattovich G, Giustina G, Realdi G, et al. European Concerted Action on Viral Hepatitis (EUROHEP) Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology. 1997;26:1338–1342
  26. Carreno V, Castillo I, Molina J, et al. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol. 1992;15:102–106
  27. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med. 1991;114:629–634
  28. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971–975
  29. Lok AS, Chung HT, Liu VW, et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology. 1993;105:1833–1838
  30. Marcellin P, Bonino F, Lau GKK, et al. The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) [Pegasys®] sustain responses 2 years post-treatment. J Hepatol. 2006;44:S275

 Organized and sponsored by the Foundation for Liver Research (SLO) (Rotterdam, The Netherlands) and supported by Schering-Plough International (Kenilworth, NJ).

 E.H.C.J.B. has received speaker's honoraria from Novartis and Roche. S.V.F. has served as a consultant for Hoffman-La Roche and Schering-Plough and has received research support from Schering-Plough. H.L.A.J. has served as a consultant for Bristol-Myers Squibb, Gilead, Novartis, and Roche and has received research support from Bristol-Myers Squibb, Novartis, Roche, and Schering-Plough. The following authors have nothing to disclose: H.J.F., Y.C., K.S., J.T., F.T., T.M.K.S., T.M., U.S.A., M.S., W.T., A.J.V., and B.E.H. Potential investigator conflicts of interest have not been disclosed to study participants.

 Members of the HBV99-01 LTFU study group include the following: Belgium: F. Nevens, E. de Wit (University Hospital Gasthuisberg, Leuven); P. P. Michielsen, R. Braspenning (University Hospital, Antwerp); H. van Vlierberghe, A. de Geyter (University Hospital, Gent). Canada: E. J. Heathcote, D. Kaznowski (Toronto Western Hospital University Health Network, Toronto); S. Bojarski (Liver Disease Unit, Mount Sinai Hospital, Toronto). Denmark: L. R. Mathiesen, G. Kronborg, L. Rosenørn (Copenhagen University Hospital, Hvidovre). Germany: G. Gerken, S. Bein (University Hospital, Essen). Greece: G. Kitis (George Papanikolaou General Regional Hospital, Thessaloniki). Italy: G. B. Gaeta (Ospedale Gesù e Maria, Napoli); F. D'Antona, G. Montalto (Università di Palermo, Palermo). Malaysia: S. Sharmila (Hospital Selayang, Institute for Medical Research, Kuala Lumpur). The Netherlands: E. Verhey, G. Ramdjan, L. A. van Santen, A. Heijens, M. Ouwendijk, J. Francke, S. Diepstraten-Pas (Erasmus MC University Medical Center, Rotterdam); C. M. J. van Nieuwkerk, C. van Doorn (VU University Medical Center, Amsterdam); J. Drenth (University Medical Centre Radboud, Nijmegen); J. W. den Ouden-Muller (St Franciscus Hospital, Rotterdam); R. A. de Vries, P. van Embden (Rijnstate Hospital, Arnhem). Poland: R. Flisiak (Medical University of Białystok, Białystok). Singapore: R. Guan (Mount Elizabeth Medical Center, Singapore). Spain: M. Buti (Hospital General Universitari Pall d'Hebron, Barcelona); M. Rodriguez (Hospital Central de Asturias, Oviedo). Turkey: H. Simsek (Hacettepe University Faculty of Medicine, Ankara).

PII: S0016-5085(08)00850-0

doi: 10.1053/j.gastro.2008.05.031

Gastroenterology
Volume 135, Issue 2 , Pages 459-467 , August 2008

Article Tools

* Image Usage & Resolution